• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to secondary sidebar
  • Skip to footer

  • COVID-19
  • Opinion
  • Health IT
    • Behavioral Health
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Patient Engagement
    • Population Health Management
    • Revenue Cycle Management
    • Social Determinants of Health
  • Digital Health
    • Artificial Intelligence
    • Blockchain
    • Mobile Health
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • M&A
  • Value-based Care
    • Accountable Care (ACOs)
    • Medicare Advantage
  • Life Sciences
  • Research

Biofourmis Lands $100M to Expand AI-Powered Digital Therapeutics Platform

by Fred Pennic 09/03/2020 Leave a Comment

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print
Biofourmis Lands $100M to Expand AI-Powered Digital Therapeutics Platform

What You Should Know:

– Boston-based digital therapeutics leader Biofourmis just closed a $100 million Series C funding round led by SoftBank, bringing its total funding to $145M.  

– Biofourmis will be using the funding to develop, validate and commercialize several released and unreleased digital therapeutics solutions across cardiology, oncology, respiratory, and pain, with a focus on the United States and key Asian markets, including Asia Pacific, China, and Japan.


Biofourmis, a fast-growing global leader in digital therapeutics that powers personalized predictive care, has announced the completion of a $100 million Series C financing round led by SoftBank Vision Fund 2, with participation by existing investors Openspace Ventures, MassMutual Ventures, Sequoia Capital, and EDBI. This brings Biofourmis’ total funding to $145 million, including the $100 million Series C, a $35 million Series B in May 2019, and $10 million Series A + seed/angel investments.

In addition, Biofourmis will use the funding for developing, validating, and commercializing several released and unreleased digital therapeutics solutions across cardiology, respiratory, oncology, and pain, with a focus on the United States and key Asian markets, including Asia Pacific, China, and Japan.

Predict and prevent costly medical events with a modular, user-friendly platform.

Founded in 2015, Biofourmis discovers, develops, and delivers clinically validated software-based therapeutics to provide better outcomes for patients, advanced tools for clinicians to deliver personalized care, technology to demonstrate the value of and complement pharmacotherapy, and cost-effective solutions for payers.

Biofourmis Product Offerings

Biofourmis product portfolio includes:

BiovitalsHF: prescription software to enable early detection of heart failure exacerbation and augment guideline-directed use of heart failure medications.

RhythmAnalytics: cloud-based software for automated detection of over 15 types of cardiac arrhythmias

Biovitals Sentinel: allows for the continuous remote monitoring of critical biovitals and patient reported symptoms using Everion, an innovative new multi-sensor armband wearable.

Painfocus: augments pain management by objective assessment of pain to guide personalized therapeutic decision-making

Gaido: prescription software to continuously monitor and detect early signs of deterioration in oncology patients, pre- and post- treatment

Biovitals Research: modularized digital trial platform empowers patients and drives engagement while capturing real-time study data anytime, anywhere, from dynamic apps and connected devices

Launch of New Business Structure

In conjunction with the Series C financing announcement, Biofourmis has announced an alignment of its internal operations to enable deeper integration with clients and partners and to support ongoing innovation. The new business structure will include two verticals:

Biofourmis Therapeutics: Focuses on pioneering an entirely new category of medicine, by developing clinically validated software-based therapeutics to treat and manage patients with unmet clinical needs. These digital therapies work independently or in conjunction with pharmacotherapies—thereby augmenting drug efficacy, reducing costs and resulting in better patient outcomes.

With Biofourmis Therapeutics’ “beyond the pill” model, pharmaceutical companies prescribe the company’s digital therapeutics solution as a companion therapeutic with high-value drugs to improve efficacy and to better manage and treat patients with complex chronic conditions.

Biofourmis Health: Focuses on virtual care models to manage patients remotely as they transition from acute to post-acute care. The company’s AI-based Biovitals® Platform is layered with personalized care pathways to manage patients with heart failure, coronary artery disease, respiratory illnesses and cancer, especially those undergoing chemo/radiation therapy or CAR-T treatment.

Biofourmis Health’s “home hospital” initiative leverages the company’s AI-based remote monitoring to lower healthcare costs—through reductions in length of stay, readmissions and emergency department visits, among other measures—and to improve patient outcomes by enabling clinicians to remotely monitor patients and intervene up to 21 hours in advance of when a medical crisis would have otherwise occurred.

“COVID-19 is pushing remote monitoring and digital therapeutics to the forefront of medicine,” said Biofourmis CEO Kuldeep Singh Rajput. “Our vision is to use digital medicine to empower patients, clinicians and researchers everywhere by providing software-as-a-treatment for patients with unmet clinical needs, from post-acute care to optimal medication therapy. With this new funding, we will accelerate our global expansion, advance our digital therapeutics pipeline, develop additional care pathways and drive deeper integration with our health system, hospital, pharmaceutical and clinical research clients and partners.”

“In the last seven months, healthcare has fast-forwarded by at least five years,” Rajput said. “Despite a challenging global economic environment due to the COVID-19 pandemic, we expect that our latest funding round will accelerate Biofourmis’ plans to rapidly scale to support more healthcare provider, pharmaceutical and health plan clients across the world. We will continue to drive an evolution toward a more personalized and predictive remote method of care delivery that patients prefer and that enables better outcomes.”

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

Tagged With: Acute Care, AI, Biofourmis, cancer, care pathways, clinical research, cloud, Digital medicine, Digital Therapeutics, Heart, medication, model, Oncology, Pain Management, Partners, Payers, post-acute care, Virtual Care

Get in-depth healthcare technology analysis and commentary delivered straight to your email weekly

Reader Interactions

Primary Sidebar

Subscribe to HIT Consultant

Latest insightful articles delivered straight to your inbox weekly.

Submit a Tip or Pitch

Knowledge Hub

10 Critical KPIs Every Successful Healthcare Organization is Implementing10 Critical KPIs Every Successful Healthcare Organization is Implementing

How to Build Hybrid Care Models Around Remote Patient Monitoring

How to Build Hybrid Care Models Around Remote Patient Monitoring

Most Popular

Recent Digital Health Partnerships

Roundups: 15 Recent Digital Health Strategic Partnerships

Recent Digital Health Executive Hires & Board Appointments

Digital Health Executive Hires: Practice Better Appoints CEO, HHAeXchange, Intelerad, Tegria, Others

M&A: Florence Acquires Virtual Care Solution Zipnosis

M&A: Florence Acquires Virtual Care Solution Zipnosis

Adopting Value-Based Care Models for Autism Care Is Imperative

Why Adopting Value-Based Care Models for Autism Care Is Imperative

UNC Health to Pilot Epic, Microsoft’s Generative AI Tool

UNC Health to Pilot Epic, Microsoft’s Generative AI Tool

Vanderbilt University Medical Center Taps Philips Reduce Carbon Footprint

Vanderbilt University Medical Center Taps Philips to Reduce Carbon Footprint

Denials Management Named Most Time-Consuming Task in RCM

Denials Management Named Most Time-Consuming Task in RCM

How AI Can Eliminate Surprise Bills, Improve Payment Integrity

AI Can Eliminate Surprise Bills, Improve Payment Integrity

Q/A: IQVIA’s Global Lead Talks Unlocking AI for Drug Repurposing

M&A: Kaiser Acquires Geisinger, Forms Risant Health

5 Executives Weigh in on VBC Impact on Kaiser/Geisinger Deal

Secondary Sidebar

Footer

Company

  • About Us
  • Advertise with Us
  • Reprints and Permissions
  • 2023 Editorial Calendar
  • Submit An Op-Ed
  • Contact
  • Subscribe

Editorial Coverage

  • Opinion
  • Health IT
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Population Health Management
    • Revenue Cycle Management
  • Digital Health
    • Artificial Intelligence
    • Blockchain Tech
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • Value-Based Care
    • Accountable Care
    • Medicare Advantage

Connect

Subscribe to HIT Consultant Media

Latest insightful articles delivered straight to your inbox weekly

Copyright © 2023. HIT Consultant Media. All Rights Reserved. Privacy Policy |